Cingulate Announces Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Portfolio Pulse from Benzinga Newsdesk
Biopharmaceutical company Cingulate Inc. (NASDAQ:CING) has announced positive top-line results from its Phase 3 adult trial of lead candidate CTx-1301 (dexmethylphenidate), a treatment for attention deficit/hyperactivity disorder (ADHD). The drug is being developed as a once-daily stimulant medication, pending approval from the U.S. Food and Drug Administration (FDA).
July 11, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cingulate Inc.'s positive Phase 3 trial results for its ADHD treatment CTx-1301 could potentially boost its stock in the short term, pending FDA approval.
Positive clinical trial results often lead to a boost in a biopharmaceutical company's stock as it indicates progress in the drug development process. The announcement of positive Phase 3 results for Cingulate's lead candidate CTx-1301 could therefore lead to a short-term increase in its stock price. However, the final impact will also depend on the FDA's decision regarding the approval of the drug.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100